Targeting of c-Met and urokinase expressing human glioma cell lines by retrovirus vector displaying single-chain variable fragment antibody

Cancer Biology and Therapy

Volumn 4, Issue 9, 2005, Pages 987-992

  Solly, Sounkary K ^a   Nguyen, Tuan Huy ^a,b   Weber, Anne ^a   Horellou, Philippe ^a,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c EMI 00 20   (France)

Author keywords

Amphotropic; c Met; Gene therapy; Hepatocyte Growth Factor; Retrovirus; Targeting; Urokinase

Indexed keywords

RETROVIRUS VECTOR; SCATTER FACTOR RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ARTICLE; CANCER CELL CULTURE; CHIMERA; CONTROLLED STUDY; ENVELOPE GENE; GENE TARGETING; GLIOMA; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS INFECTION;

EID: 27744439025     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.9.1916     Document Type: Article

References (58)

1. Tooth HH. Some observations on the growth and survival period of intracranial tumors based on the review of 500 cases, with special reference to the pathology of gliomata. Brain 1912; 35:61-108.
2. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64:769-74.
3. Gaya A, Rees J, Greenstein A, Stebbing J. The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 2002; 28:115-20.
4. Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 2002; 25:606-11.
5. Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology 2002; 58:1109-12.
6. Mulligan RC. The basic science of gene therapy. Science 1993; 260:926-32.
7. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy-what have we learned? J Neurooncol 2003; 65:227-36.
8. Miller DG, Edwards RH, Miller AD. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 1994; 91:78-82.
9. Kavanaugh MP, Kabat D. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int 1996; 49:959-63.
10. Barnett AL, Cunningham JM. Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion. J Virol 2001; 75:9096-105.
11. Ragheb JA, Anderson WF. Uncoupled expression of Moloney murine leukemia virus envelope polypeptides SU and TM: A functional analysis of the role of TM domains in viral entry. J Virol 1994; 68:3207-19.
12. Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995; 69:6314-22.
13. Fielding AK, Maurice M, Morling FJ, Cosset FL, Russell SJ. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and non-hematopoietic cells. Blood 1998; 91:1802-9.
14. Chadwick MP, Morling FJ, Cosset FL, Russell SJ. Modification of retroviral tropism by display of IGF-I. J Mol Biol 1999; 285:485-94.
15. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997; 8:729-38.
16. Peng KW, Vile R, Cosset FL, Russell S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999; 6:1552-7.
17. Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther 2003; 10:840-9.
18. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996; 16:1115-25.
19. Hirose Y, Kojima M, Sagoh M, Hayashi T, Murakami H, Shimazaki K, Yoshida K, Kawase T. Clinical importance of c-Met protein expression in high grade astrocytic tumors. Neurol Med Chir (Tokyo) 1998; 38:851-9.
20. Moriyama T, Kataoka H, Koono M, Wakisaka S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: Evidence for a role in progression of astrocytic tumors (Review). Int J Mol Med 1999; 3:531-6.
21. Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999; 17:517-30.
22. Welch WC, Kornblith PL, Michalopoulos GK, Petersen BE, Beedle A, Gollin SM, Goldfarb RH. Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells. Anticancer Res 1999; 19:1635-40.
23. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-4.
24. Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir (Wien) 1998; 140:377-86.
25. Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY, Yacoub IZ. Upregulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 1995; 146:1150-60.
26. Vassalli JD, Pepper MS. Tumour biology. Membrane proteases in focus. Nature 1994; 370:14-5.
27. Gunzler WA, Steffens GJ, Otting F, Buse G, Flohe L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem 1982; 363:133-41.
28. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968; 74:465-86.
29. 1 arrest in vitro. J Cell Physiol 1979; 99:43-54.
30. Gross JL, Behrens DL, Mullins DE, Kornblith PL, Dexter DL. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res 1988; 48:291-6.
31. Rosenblum ML, Dougherty DV, Reese C, Wilson CB. Potentials and possible pitfalls of human stem cell analysis. Cancer Chemother Pharmacol 1981; 6:227-35.
32. Pfreundschuh M, Shiku H, Takahashi T, Ueda R, Ransohoff J, Oettgen HF, Old LJ. Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci USA 1978; 75:5122-6.
33. Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 2000; 6:327-31.
34. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. Embo J 1992; 11:4825-33.
35. Mizuno K, Tanoue Y, Okano I, Harano T, Takada K, Nakamura T. Purification and characterization of hepatocyte growth factor (HGF)-converting enzyme: Activation of pro-HGF. Biochem Biophys Res Commun 1994; 198:1161-9.
36. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69:7430-6.
37. Nguyen TH, Pages JC, Farge D, Briand P, Weber A. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 1998; 9:2469-79.
38. Ried S, Jager C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem 1999; 274:16377-86.
39. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57:5391-8.
40. Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID, Johnston P. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997; 76:565-77.
41. Chattopadhyay N, Tfelt-Hansen J, Brown EM. PKC, p42/44 MAPK and p38 MAPK regulate hepatocyte growth factor secretion from human astrocytoma cells. Brain Res Mol Brain Res 2002; 102:73-82.
42. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. Embo J 1991; 10:2867-78.
43. Matsumoto K, Nakamura T. Roles of HGF as a pleiotropic factor in organ regeneration. Exs 1993; 65:225-49.
44. Grigioni WF, Florentino M, D'Errico A, Ponzetto A, Crepaldi T, Prat M, Comoglio PM. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology 1995; 21:1543-6.
45. Ueki T, Nakata K, Mawatari F, Tsuruta S, Ido A, Ishikawa H, Nakao K, Kato Y, Ishii N, Eguchi K. Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice. Int J Mol Med 1998; 1:671-5.
46. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. Faseb J 2002; 16:108-10.
47. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72:1-22.
48. Abounader R, Ranganathan S, Kim BY, Nichols C, Laterra J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem 2001; 76:1497-508.
49. Yano H, Hara A, Murase S, Hayashi K, Ando H, Shinoda J, Shimokawa K, Sakai N. Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. Brain Tumor Pathol 2001; 18:7-12.
50. Moriyama T, Kataoka H, Tsubouchi H, Koono M. Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro. FEBS Lett 1995; 372:78-82.
51. Kurre P, Kiem HP, Morris J, Heyward S, Battini JL, Miller AD. Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor. J Virol 1999; 73:495-500.
52. Battini JL, Rodrigues P, Muller R, Danos O, Heard JM. Receptor-binding properties of a purified fragment of the 4070A amphotropic murine leukemia virus envelope glycoprotein. J Virol 1996; 70:4387-93.
53. Nilson BH, Morling FJ, Cosset FL, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996; 3:280-6.
54. Pinter A, Kopelman R, Li Z, Kayman SC, Sanders DA. Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes. J Virol 1997; 71:8073-7.
55. Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset FL. Receptor cooperation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding. Embo J 1997; 10:1214-23.
56. Martin F, Neil S, Kupsch J, Maurice M, Cosset F, Collins M. Retrovirus targeting by tropism restriction to melanoma cells. J Virol 1999; 73:6923-9.
57. Martin F, Chowdhury S, Neil S, Phillipps N, Collins MK. Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol Ther 2002; 5:269-74.
58. Martin F, Chowdhury S, Neil SJ, Chester KA, Cosset FL, Collins MK. Targeted retroviral infection of tumor cells by receptor cooperation. J Virol 2003; 77:2753-6.